Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported that non-executive director Dr Hal Barron acquired additional American Depositary Shares through his GSK 401(k) plan. The purchase resulted from the reinvestment of dividends, leading to the acquisition of 64 ADS at a price of $59.5200 per ADS.
The transaction took place on 2026-02-20 on the New York Stock Exchange (XNYS). This reflects automatic plan-based dividend reinvestment rather than an open‑market discretionary trade.
GSK plc has agreed to acquire Canada-based 35Pharma Inc., a private clinical-stage biopharma company, for $950 million in cash at closing. The deal adds HS235, a potential best-in-class activin signalling inhibitor for cardiopulmonary diseases, to GSK’s pipeline.
HS235 has completed phase I trials in healthy volunteers, with studies starting in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction. GSK highlights HS235’s design to lower bleeding risk and its potential metabolic benefits, aiming to strengthen its Respiratory, Immunology and Inflammation portfolio in a pulmonary hypertension market forecast to reach $18 billion by 2032.
GSK plc reports that, acting through BNP Paribas, it repurchased 477,000 ordinary shares on 24 February 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,175.00p and 2,217.00p per share, with a volume-weighted average price of 2,200.50p, and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased a total of 2,706,000 ordinary shares. After this latest transaction, the company holds 242,597,094 ordinary shares in treasury and has 4,073,555,332 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. GSK states that treasury shares now represent 5.96% of its voting rights.
GSK plc reported routine insider share transactions for two senior figures under its executive savings plans. Non-Executive Director Dr Hal Barron acquired 2,007.552 notional American Depositary Shares at $59.5200 per ADS on 20 February 2026 through automatic dividend reinvestment.
On the same date, James Ford, SVP and Group General Counsel, acquired 47.460 notional ADS, also at $59.5200 per ADS, via dividend reinvestment in his GSK Executive Supplemental Savings Plan account. Both transactions took place on the New York Stock Exchange.
GSK plc reports that, under its existing share buyback programme, it repurchased 462,000 ordinary shares of 31¼ pence each on 23 February 2026 through BNP Paribas. The lowest, highest and volume‑weighted average prices were 2,184.00p, 2,213.00p and 2,200.95p per share.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 2,229,000 ordinary shares. After these purchases, it holds 242,120,094 shares in treasury and has 4,074,032,332 ordinary shares in issue, which is also the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, treasury shares now represent 5.94% of its voting rights. The filing also lists detailed trade-by-trade information across the London Stock Exchange and Cboe Europe venues, showing how the buyback was executed throughout the day.
GSK plc reports that, on 20 February 2026, it repurchased 467,000 ordinary shares of 31¼ pence each through BNP Paribas as part of its existing share buyback programme, at a volume-weighted average price of 2,223.53p, within a price range of 2,200.00p to 2,242.00p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 1,767,000 ordinary shares. Following this transaction, it holds 241,658,094 shares in treasury and has 4,074,494,332 ordinary shares in issue, which equals the total voting rights. Treasury shares represent 5.93% of voting rights.
GSK plc reported a share purchase by one of its board members. Independent Non-Executive Director Wendy Becker bought 3,334 ordinary shares of GSK at a price of £22.1926 per share. The transaction took place on 20 February 2026 on the London Stock Exchange.
GSK plc reports that, acting through BNP Paribas, it bought back 470,000 ordinary shares of 31¼ pence each on 19 February 2026. The purchases were made at prices between 2,217.00p and 2,264.00p per share, with a volume-weighted average price of 2,243.09p.
The shares will be held as treasury shares under GSK’s existing buyback programme, pursuant to a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 1,300,000 shares. After this transaction, it holds 241,191,094 shares in treasury and has 4,074,951,475 shares in issue, which equals 4,074,951,475 voting rights. Treasury shares represent 5.92% of voting rights under the Disclosure Guidance and Transparency Rules.
GSK plc reported a transaction involving Chief Scientific Officer Tony Wood related to its Deferred Investment Award Programme. On 18 February 2026, 25% of an award granted on 18 February 2021 vested. In connection with this vesting, Wood will receive a cash payment of £204,048.58, before tax, corresponding to 8,996.851 notional ordinary shares of 31¼ pence each, valued at £22.68 per share. This is recorded as a single transaction under GSK’s remuneration arrangements for senior management.
GSK plc reports that, acting through BNP Paribas, it repurchased 410,000 ordinary shares on 18 February 2026 as part of its existing share buyback programme. The shares, with a volume-weighted average price of 2,268.77p, will be held as treasury shares.
Since 17 February 2026, GSK has bought back a total of 830,000 ordinary shares. After these transactions, it holds 240,721,094 shares in treasury and has 4,075,421,475 ordinary shares in issue, which is also the total number of voting rights.
The company states that treasury shares now represent 5.91% of the voting rights. Detailed schedules list the prices and volumes of trades executed on the London Stock Exchange and Cboe Europe venues as part of this programme.